Lin SH - Search Results

1

Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment.

Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. Lee YC, et al. Among authors: lin sh. Mol Cell Proteomics. 2015 Mar;14(3):471-83. doi: 10.1074/mcp.M114.039909. Epub 2014 Dec 19. Mol Cell Proteomics. 2015. PMID: 25527621 Free PMC article.

2

NudC associates with Lis1 and the dynein motor at the leading pole of neurons.

Aumais JP, Tunstead JR, McNeil RS, Schaar BT, McConnell SK, Lin SH, Clark GD, Yu-Lee LY. Aumais JP, et al. Among authors: lin sh. J Neurosci. 2001 Dec 15;21(24):RC187. doi: 10.1523/JNEUROSCI.21-24-j0002.2001. J Neurosci. 2001. PMID: 11734602 Free PMC article.

3

Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1.

Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH. Volpert O, et al. Among authors: lin sh. J Biol Chem. 2002 Sep 20;277(38):35696-702. doi: 10.1074/jbc.M205319200. Epub 2002 Jul 16. J Biol Chem. 2002. PMID: 12122002 Free article.

4

Stem-cell origin of metastasis and heterogeneity in solid tumours.

Tu SM, Lin SH, Logothetis CJ. Tu SM, et al. Among authors: lin sh. Lancet Oncol. 2002 Aug;3(8):508-13. doi: 10.1016/s1470-2045(02)00820-3. Lancet Oncol. 2002. PMID: 12147437 Review.

5

Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features.

Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Tu SM, et al. Among authors: lin sh. Cancer. 2002 May 15;94(10):2610-7. doi: 10.1002/cncr.10546. Cancer. 2002. PMID: 12173328 Free article.

6

Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470.

Pu YS, Do KA, Luo W, Logothetis CJ, Lin SH. Pu YS, et al. Among authors: lin sh. Anticancer Drugs. 2002 Aug;13(7):743-9. doi: 10.1097/00001813-200208000-00009. Anticancer Drugs. 2002. PMID: 12187331

7

Antitumor activity of the 16-kDa prolactin fragment in prostate cancer.

Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH. Kim J, et al. Among authors: lin sh. Cancer Res. 2003 Jan 15;63(2):386-93. Cancer Res. 2003. PMID: 12543792

8

Role for NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesis.

Aumais JP, Williams SN, Luo W, Nishino M, Caldwell KA, Caldwell GA, Lin SH, Yu-Lee LY. Aumais JP, et al. Among authors: lin sh. J Cell Sci. 2003 May 15;116(Pt 10):1991-2003. doi: 10.1242/jcs.00412. Epub 2003 Apr 1. J Cell Sci. 2003. PMID: 12679384

9

Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells.

Galfione M, Luo W, Kim J, Hawke D, Kobayashi R, Clapp C, Yu-Lee LY, Lin SH. Galfione M, et al. Among authors: lin sh. Protein Expr Purif. 2003 Apr;28(2):252-8. doi: 10.1016/s1046-5928(02)00639-3. Protein Expr Purif. 2003. PMID: 12699689

10

Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Tu SM, Lin SH, Logothetis C. Tu SM, et al. Among authors: lin sh. J Natl Cancer Inst. 2003 Aug 6;95(15):1174-5; author reply 1175. doi: 10.1093/jnci/djg020. J Natl Cancer Inst. 2003. PMID: 12902452 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,741 results

Search Page

Filters